Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer

Stock Information for Cardiff Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cardiff Oncology Inc.

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference
Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research
Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.